Skip to content

Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q3Scopus Q3
Citation
Web of Science 4
JCR IF
JCR 2015 1.68
ISSN
0378-7966

Authors

  1. Lee, Byung-yoFirst authorCollege of Pharmacy, Chungnam National University, Daejeon, South Korea
  2. Kwon, Kwang-ilCollege of Pharmacy, Chungnam National University, Daejeon, South Korea
  3. Kim, MinsooCollege of Pharmacy, Pusan National University, Busan, South Korea
  4. Baek, In-hwanCorresponding authorCollege of Pharmacy, Kyungsung University, Busan, South Korea

Abstract

Etanercept was approved by the Food and Drug Administration (FDA) in 2010 as a biologic agent for the treatment of rheumatoid arthritis (RA). The aim of the study was to investigate the pharmacokinetic properties of etanercept after intravenous and subcutaneous injection in rats. The plasma concentration of etanercept was determined using an enzyme-linked immunosorbent assay (ELISA). Intravenous and subcutaneous administration of 2 mg/kg of etanercept to rats showed that etanercept was slowly absorbed (time to reach the peak drug concentration [T (max)] = 1.60 days, bioavailability [F] = 47.18 %) and slowly eliminated (half-life [t (1/2)], 2.33 days after intravenous administration and 3.31 days after subcutaneous administration). The area under the curve values on day 13 (AUC(13day)) were 121.25 +/- 14.37 and 48.56 +/- 6.78 mu g day/mL after intravenous and subcutaneous administration, respectively. A two-compartment model with Michaelis-Menten elimination kinetics (V (max) = 94.28 A mu g/day; K (m) = 10.88 A mu g/mL) was used to describe the pharmacokinetic profile of etanercept. Our results describe the pharmacokinetic profile of etanercept, and these results could be used for the development of etanercept biosimilars.

Keywords

EtanerceptPharmacokineticsMichaelis-Menten kineticsSubcutaneousFUSION PROTEINPHARMACOKINETICS

Identifiers

WoS UID
000380254700013